RxDoctor Payments Data

Saeed Ahmad, MD

Cardiovascular Disease · Oklahoma City, OKNPI 1285733881

Payments from drug & device makers

$788in general payments, 2019–2025

Across 26 payments — averaging $30.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$367
  • Novartis$84
  • Amgen$81
  • Boehringer Ingelheim$51
  • Irhythm Technologies, Inc.$38
  • Merck$33
  • plus $133 from 7 others

What the payments were for

  • Travel & lodging$36747%
  • Food & beverage$42053%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$788 in reported general payments places this provider in the 25th percentile of 164 cardiovascular disease providers in Oklahoma.

See all cardiovascular disease providers in Oklahoma

Medicare billing

Part B allowed, 2024
$92,346
Medicare patients
592
Services billed
1,439

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban120$136,089
EntrestoSacubitril/Valsartan26$15,562
Ranolazine ErRanolazine33$3,338
Atorvastatin Calcium191$2,784
Amlodipine Besylate153$2,353
Metoprolol Tartrate230$2,023
Carvedilol109$1,394
Losartan Potassium66$1,242
ClopidogrelClopidogrel Bisulfate115$1,196
Lisinopril98$1,148
Metoprolol Succinate46$812
Nitroglycerin38$621
Amiodarone Hcl27$584
Rosuvastatin Calcium32$560
Olmesartan Medoxomil16$539

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$84$15,56226 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 164 cardiovascular disease providers in Oklahoma.

Other cardiovascular disease in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →